{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:02:23Z","timestamp":1790899343163,"version":"4.1.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T00:00:00Z","timestamp":1561075200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T00:00:00Z","timestamp":1561075200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG 17585"],"award-info":[{"award-number":["IG 17585"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG 18815"],"award-info":[{"award-number":["IG 18815"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RC18-2638151"],"award-info":[{"award-number":["RC18-2638151"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["5x1000"],"award-info":[{"award-number":["5x1000"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2016-02362288"],"award-info":[{"award-number":["RF-2016-02362288"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13046-019-1238-4","type":"journal-article","created":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T16:02:55Z","timestamp":1561132975000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A"],"prefix":"10.1186","volume":"38","author":[{"given":"Simona","family":"Caporali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Amaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauretta","family":"Levati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Alvino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Miguel","family":"Lacal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Mastroeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Ruffini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bonmassar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Carlo","family":"Antonini Cappellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Felli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Car\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Pfeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"D\u2019Atri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,21]]},"reference":[{"key":"1238_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.3","volume":"1","author":"D Schadendorf","year":"2015","unstructured":"Schadendorf D, Fisher DE, Garbe C, Gershenwald JE, Grob J-J, Halpern A, et al. Melanoma. Nat Rev Dis Prim. 2015;1:15003.","journal-title":"Nat Rev Dis Prim."},{"key":"1238_CR2","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong S-J, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199\u2013206.","journal-title":"J Clin Oncol."},{"key":"1238_CR3","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s40265-018-0963-x","volume":"78","author":"M Shirley","year":"2018","unstructured":"Shirley M. Encorafenib and Binimetinib: First Global Approvals. Drugs. 2018;78:1277\u201384.","journal-title":"Drugs."},{"key":"1238_CR4","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ejca.2017.06.028","volume":"83","author":"S Ugurel","year":"2017","unstructured":"Ugurel S, R\u00f6hmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies\u2013update 2017. Eur J Cancer. 2017;83:247\u201357.","journal-title":"Eur J Cancer."},{"key":"1238_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ejca.2016.12.010","volume":"73","author":"T Amaral","year":"2017","unstructured":"Amaral T, Sinnberg T, Meier F, Krepler C, Levesque M, Niessner H, et al. The mitogen-activated protein kinase pathway in melanoma part I \u2013 Activation and primary resistance mechanisms to BRAF inhibition. Eur J Cancer. 2017;73:85\u201392.","journal-title":"Eur J Cancer."},{"key":"1238_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ejca.2016.12.012","volume":"73","author":"T Amaral","year":"2017","unstructured":"Amaral T, Sinnberg T, Meier F, Krepler C, Levesque M, Niessner H, et al. MAPK pathway in melanoma part II \u2013 secondary and adaptive resistance mechanisms to BRAF inhibition. Eur J Cancer. 2017;73:93\u2013101.","journal-title":"Eur J Cancer."},{"key":"1238_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ejca.2016.04.005","volume":"62","author":"SJ Welsh","year":"2016","unstructured":"Welsh SJ, Rizos H, Scolyer RA, Long GV. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next? Eur J Cancer. 2016;62:76\u201385.","journal-title":"Eur J Cancer."},{"key":"1238_CR8","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.cell.2015.07.061","volume":"162","author":"W Hugo","year":"2015","unstructured":"Hugo W, Shi H, Sun L, Piva M, Song C, Kong X, et al. Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. Cell. 2015;162:1271\u201385.","journal-title":"Cell."},{"key":"1238_CR9","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1016\/j.ejca.2015.08.022","volume":"51","author":"DB Johnson","year":"2015","unstructured":"Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao S, et al. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur J Cancer. 2015;51:2792\u20139.","journal-title":"Eur J Cancer."},{"key":"1238_CR10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cell.2018.03.006","volume":"173","author":"DP Bartel","year":"2018","unstructured":"Bartel DP. Metazoan MicroRNAs. Cell. 2018;173:20\u201351.","journal-title":"Cell."},{"key":"1238_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13046-016-0375-2","volume":"35","author":"L Paladini","year":"2016","unstructured":"Paladini L, Fabris L, Bottai G, Raschioni C, Calin GA, Santarpia L. Targeting microRNAs as key modulators of tumor immune response. J Exp Clin Cancer Res. 2016;35:103.","journal-title":"J Exp Clin Cancer Res."},{"key":"1238_CR12","doi-asserted-by":"publisher","first-page":"5133","DOI":"10.1002\/jcp.26395","volume":"233","author":"CL Ross","year":"2018","unstructured":"Ross CL, Kaushik S, Valdes-Rodriguez R, Anvekar R. MicroRNAs in cutaneous melanoma: Role as diagnostic and prognostic biomarkers. J Cell Physiol. 2018;233:5133\u201341.","journal-title":"J Cell Physiol."},{"key":"1238_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd.2016.246","volume":"16","author":"R Rupaimoole","year":"2017","unstructured":"Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16:203\u201322.","journal-title":"Nat Rev Drug Discov."},{"key":"1238_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ebiom.2016.09.017","volume":"12","author":"MY Shah","year":"2016","unstructured":"Shah MY, Ferrajoli A, Sood AK, Lopez-Berestein G, Calin GA. microRNA Therapeutics in Cancer \u2013 An Emerging Concept. EBioMedicine. 2016;12:34\u201342.","journal-title":"EBioMedicine."},{"key":"1238_CR15","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/pcmr.12346","volume":"28","author":"M Mione","year":"2015","unstructured":"Mione M, Bosserhoff A. MicroRNAs in melanocyte and melanoma biology. Pigment Cell Melanoma Res. 2015;28:340\u201354.","journal-title":"Pigment Cell Melanoma Res."},{"key":"1238_CR16","doi-asserted-by":"publisher","first-page":"22262","DOI":"10.18632\/oncotarget.14763","volume":"8","author":"L Fattore","year":"2017","unstructured":"Fattore L, Costantini S, Malpicci D, Ruggiero CF, Ascierto PA, Croce CM, et al. MicroRNAs in melanoma development and resistance to target therapy. Oncotarget. 2017;8:22262\u201378.","journal-title":"Oncotarget."},{"key":"1238_CR17","first-page":"1350","volume":"7","author":"M Geretto","year":"2017","unstructured":"Geretto M, Pulliero A, Rosano C, Zhabayeva D, Bersimbaev R, Izzotti A. Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators. Am J Cancer Res. 2017;7:1350\u201371.","journal-title":"Am J Cancer Res."},{"key":"1238_CR18","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/pcmr.12379","volume":"28","author":"S Liu","year":"2015","unstructured":"Liu S, Tetzlaff MT, Wang T, Yang R, Xie L, Zhang G, et al. miR-200c\/Bmi1 Axis and Epithelial-Mesenchymal Transition Contribute to Acquired Resistance to BRAF Inhibitor Treatment. Pigment Cell Melanoma Res. 2015;28:431\u201341.","journal-title":"Pigment Cell Melanoma Res."},{"key":"1238_CR19","doi-asserted-by":"crossref","first-page":"53558","DOI":"10.18632\/oncotarget.10669","volume":"7","author":"X Sun","year":"2016","unstructured":"Sun X, Li J, Sun Y, Zhang Y, Dong L, Shen C, et al. miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR\/IGF-1R\/CRAF and inhibiting the MAPK and PI3K\/AKT signaling pathways. Oncotarget. 2016;7:53558\u201370.","journal-title":"Oncotarget."},{"key":"1238_CR20","doi-asserted-by":"publisher","first-page":"E5005","DOI":"10.1073\/pnas.1607753113","volume":"113","author":"L Fattore","year":"2016","unstructured":"Fattore L, Mancini R, Acunzo M, Romano G, Lagan\u00e0 A, Pisanu ME, et al. miR-579-3p controls melanoma progression and resistance to target therapy. Proc Natl Acad Sci. 2016;113:E5005\u201313.","journal-title":"Proc Natl Acad Sci."},{"key":"1238_CR21","doi-asserted-by":"publisher","unstructured":"Fattore L, Ruggiero CF, Pisanu ME, Liguoro D, Cerri A, Costantini S, et al. Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma. Cell Death Differ. 2018. \n                    https:\/\/doi.org\/10.1038\/s41418-018-0202-5.","DOI":"10.1038\/s41418-018-0202-5."},{"key":"1238_CR22","doi-asserted-by":"publisher","first-page":"4428","DOI":"10.18632\/oncotarget.6599","volume":"7","author":"E Vergani","year":"2016","unstructured":"Vergani E, Di GL, Dugo M, Rigoletto S, Ruggeri R, Perrone F, et al. Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b. Oncotarget. 2016;7:4428\u201341.","journal-title":"Oncotarget."},{"key":"1238_CR23","doi-asserted-by":"publisher","first-page":"947","DOI":"10.4143\/crt.2016.280","volume":"49","author":"J-H Kim","year":"2017","unstructured":"Kim J-H, Ahn J-H, Lee M. Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF. Cancer Res Treat. 2017;49:947\u201359.","journal-title":"Cancer Res Treat."},{"key":"1238_CR24","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/pcmr.12578","volume":"30","author":"L Koetz-Ploch","year":"2017","unstructured":"Koetz-Ploch L, Hanniford D, Dolgalev I, Sokolova E, Zhong J, D\u00edaz-Mart\u00ednez M, et al. MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway. Pigment Cell Melanoma Res. 2017;30:328\u201338.","journal-title":"Pigment Cell Melanoma Res."},{"key":"1238_CR25","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1158\/0008-5472.CAN-17-1318","volume":"78","author":"M D\u00edaz-Mart\u00ednez","year":"2018","unstructured":"D\u00edaz-Mart\u00ednez M, Benito-Jard\u00f3n L, Alonso L, Koetz-Ploch L, Hernando E, Teixid\u00f3 J. miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma. Cancer Res. 2018;78:1017\u201330.","journal-title":"Cancer Res."},{"key":"1238_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056824","volume":"8","author":"N Felli","year":"2013","unstructured":"Felli N, Felicetti F, Lustri AM, Errico MC, Bottero L, Cannistraci A, et al. miR-126&126* Restored Expressions Play a Tumor Suppressor Role by Directly Regulating ADAM9 and MMP7 in Melanoma. PLoS One. 2013;8:e56824.","journal-title":"PLoS One."},{"key":"1238_CR27","doi-asserted-by":"publisher","first-page":"113472","DOI":"10.18632\/oncotarget.23052","volume":"8","author":"S Caporali","year":"2017","unstructured":"Caporali S, Alvino E, Lacal PM, Ruffini F, Levati L, Bonmassar L, et al. Targeting the PTTG1 oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib. Oncotarget. 2017;8:113472\u201393.","journal-title":"Oncotarget."},{"key":"1238_CR28","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.3892\/ijo.2016.3594","volume":"49","author":"S Caporali","year":"2016","unstructured":"Caporali S, Alvino E, Lacal PM, Levati L, Giurato G, Memoli D, et al. Targeting the PI3K\/AKT\/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor. Int J Oncol. 2016;49:1164\u201374.","journal-title":"Int J Oncol."},{"key":"1238_CR29","doi-asserted-by":"publisher","first-page":"5116","DOI":"10.1073\/pnas.091062498","volume":"98","author":"VG Tusher","year":"2001","unstructured":"Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001;98:5116\u201321.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"1238_CR30","doi-asserted-by":"publisher","first-page":"R118","DOI":"10.1186\/gb-2008-9-7-r118","volume":"9","author":"VT Chu","year":"2008","unstructured":"Chu VT, Gottardo R, Raftery AE, Bumgarner RE, Yeung K. MeV+R: using MeV as a graphical user interface for Bioconductor applications in microarray analysis. Genome Biol. 2008;9:R118.","journal-title":"Genome Biol."},{"key":"1238_CR31","doi-asserted-by":"publisher","unstructured":"Agarwal V, Bell GW, Nam J-W, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife. 2015. \n                    https:\/\/doi.org\/10.7554\/eLife.05005\n                    \n                  .","DOI":"10.7554\/eLife.05005"},{"key":"1238_CR32","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jbi.2011.05.002","volume":"44","author":"H Dweep","year":"2011","unstructured":"Dweep H, Sticht C, Pandey P, Gretz N. miRWalk \u2013 Database: Prediction of possible miRNA binding sites by \u201cwalking\u201d the genes of three genomes. J Biomed Inform. 2011;44:839\u201347.","journal-title":"J Biomed Inform."},{"key":"1238_CR33","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44:W90\u20137.","journal-title":"Nucleic Acids Res."},{"key":"1238_CR34","first-page":"478","volume":"66","author":"S Caporali","year":"2004","unstructured":"Caporali S, Falcinelli S, Starace G, Russo MT, Bonmassar E, Jiricny J, et al. DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system. Mol Pharmacol. 2004;66:478\u201391.","journal-title":"Mol Pharmacol."},{"key":"1238_CR35","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13046-017-0577-2","volume":"36","author":"MG Atzori","year":"2017","unstructured":"Atzori MG, Tentori L, Ruffini F, Ceci C, Lisi L, Bonanno E, et al. The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells. J Exp Clin Cancer Res. 2017;36:106.","journal-title":"J Exp Clin Cancer Res."},{"key":"1238_CR36","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.3892\/or.2013.2633","volume":"30","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Wang X, Xu B, Wang B, Wang Z, Liang Y, et al. Epigenetic silencing of miR-126 contributes to tumor invasion and angiogenesis in colorectal cancer. Oncol Rep. 2013;30:1976\u201384.","journal-title":"Oncol Rep."},{"key":"1238_CR37","doi-asserted-by":"crossref","first-page":"110257","DOI":"10.18632\/oncotarget.22628","volume":"8","author":"ML Fisher","year":"2017","unstructured":"Fisher ML, Grun D, Adhikary G, Xu W, Eckert RL. Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells. Oncotarget. 2017;8:110257\u201372.","journal-title":"Oncotarget."},{"key":"1238_CR38","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1172\/JCI70156","volume":"124","author":"JN Anastas","year":"2014","unstructured":"Anastas JN, Kulikauskas RM, Tamir T, Rizos H, Long GV, Von Euw EM, et al. WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors. J Clin Invest. 2014;124:2877\u201390.","journal-title":"J Clin Invest."},{"key":"1238_CR39","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.ccell.2015.03.008","volume":"27","author":"E Hirata","year":"2015","unstructured":"Hirata E, Girotti MR, Viros A, Hooper S, Spencer-Dene B, Matsuda M, et al. Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin \u03b21\/FAK Signaling. Cancer Cell. 2015;27:574\u201388.","journal-title":"Cancer Cell."},{"key":"1238_CR40","first-page":"255","volume":"8","author":"M Chi","year":"2014","unstructured":"Chi M, Ye Y, Zhang XD, Chen J. Insulin induces drug resistance in melanoma through activation of the PI3K\/Akt pathway. Drug Des Devel Ther. 2014;8:255\u201362.","journal-title":"Drug Des Devel Ther."},{"key":"1238_CR41","doi-asserted-by":"publisher","first-page":"77257","DOI":"10.18632\/oncotarget.12629","volume":"7","author":"D D\u2019Arcangelo","year":"2016","unstructured":"D\u2019Arcangelo D, Facchiano F, Nassa G, Stancato A, Antonini A, Rossi S, et al. PDGFR-alpha inhibits melanoma growth via CXCL10\/IP-10: a multi-omics approach. Oncotarget. 2016;7:77257\u201375.","journal-title":"Oncotarget."},{"key":"1238_CR42","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.yexmp.2013.12.004","volume":"96","author":"F Ebrahimi","year":"2014","unstructured":"Ebrahimi F, Gopalan V, Smith RA, Lam AK-Y. miR-126 in human cancers: clinical roles and current perspectives. Exp Mol Pathol. 2014;96:98\u2013107.","journal-title":"Exp Mol Pathol."},{"key":"1238_CR43","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1016\/j.bbagen.2017.04.005","volume":"1861","author":"I Kozar","year":"2017","unstructured":"Kozar I, Cesi G, Margue C, Philippidou D, Kreis S. Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells. Biochim Biophys Acta - Gen Subj. 2017;1861:2980\u201392.","journal-title":"Biochim Biophys Acta - Gen Subj."},{"key":"1238_CR44","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12885-017-3132-9","volume":"17","author":"L Shi","year":"2017","unstructured":"Shi L, Xu Z, Wu G, Chen X, Huang Y, Wang Y, et al. Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J. BMC Cancer. 2017;17:138.","journal-title":"BMC Cancer."},{"key":"1238_CR45","doi-asserted-by":"crossref","first-page":"21719","DOI":"10.18632\/oncotarget.15559","volume":"8","author":"K Xu","year":"2017","unstructured":"Xu K, Chen G, Qiu Y, Yuan Z, Li H, Yuan X, et al. miR-503-5p confers drug resistance by targeting PUMA in colorectal carcinoma. Oncotarget. 2017;8:21719\u201332.","journal-title":"Oncotarget."},{"key":"1238_CR46","doi-asserted-by":"crossref","unstructured":"Qian Y, Wang X, Lv Z, Guo C, Yang Y, Zhang J, et al. MicroRNA-126 is downregulated in thyroid cancer cells, and regulates proliferation, migration and invasion by targeting CXCR4. Mol Med Rep. 2016;14:453\u20139.","DOI":"10.3892\/mmr.2016.5276"},{"key":"1238_CR47","first-page":"1539","volume":"29","author":"B Mitchell","year":"2014","unstructured":"Mitchell B, Mahalingam M. The CXCR4\/CXCL2 axis in cutaneous malignancies with an emphasis on melanoma. Histol Histopathol. 2014;29:1539\u201348.","journal-title":"Histol Histopathol."},{"key":"1238_CR48","first-page":"1625","volume":"27","author":"PM Lacal","year":"2005","unstructured":"Lacal PM, Ruffini F, Pagani E, D\u2019Atri S. An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells. Int J Oncol. 2005;27:1625\u201332.","journal-title":"Int J Oncol."},{"key":"1238_CR49","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1111\/j.0022-202X.2004.23460.x","volume":"123","author":"J Graells","year":"2004","unstructured":"Graells J, Vinyals A, Figueras A, Llorens A, Moreno A, Marcoval J, et al. Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. J Invest Dermatol. 2004;123:1151\u201361.","journal-title":"J Invest Dermatol."},{"key":"1238_CR50","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1046\/j.1523-1747.2000.00199.x","volume":"115","author":"PM Lacal","year":"2000","unstructured":"Lacal PM, Failla CM, Pagani E, Odorisio T, Schietroma C, Falcinelli S, et al. Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J Invest Dermatol. 2000;115:1000\u20137.","journal-title":"J Invest Dermatol."},{"key":"1238_CR51","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s11010-011-0723-7","volume":"351","author":"N Zhu","year":"2011","unstructured":"Zhu N, Zhang D, Xie H, Zhou Z, Chen H, Hu T, et al. Endothelial-specific intron-derived miR-126 is down-regulated in human breast cancer and targets both VEGFA and PIK3R2. Mol Cell Biochem. 2011;351:157\u201364.","journal-title":"Mol Cell Biochem."},{"key":"1238_CR52","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/fonc.2015.00202","volume":"5","author":"PA Ott","year":"2015","unstructured":"Ott PA, Hodi FS, Buchbinder EI. Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data. Front Oncol. 2015;5:202.","journal-title":"Front Oncol."},{"key":"1238_CR53","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s12032-008-9058-y","volume":"25","author":"F Tas","year":"2008","unstructured":"Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Circulating levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-3 (MMP-3), and BCL-2 in malignant melanoma. Med Oncol. 2008;25:431\u20136.","journal-title":"Med Oncol."},{"key":"1238_CR54","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1200\/JCO.2008.19.1106","volume":"27","author":"M Sabatino","year":"2009","unstructured":"Sabatino M, Kim-Schulze S, Panelli MC, Stroncek D, Wang E, Taback B, et al. Serum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to High-Dose Interleukin-2 Therapy. J Clin Oncol. 2009;27:2645\u201352.","journal-title":"J Clin Oncol."},{"key":"1238_CR55","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1158\/2326-6066.CIR-13-0163","volume":"2","author":"J Yuan","year":"2014","unstructured":"Yuan J, Zhou J, Dong Z, Tandon S, Kuk D, Panageas KS, et al. Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab. Cancer Immunol Res. 2014;2:127\u201332.","journal-title":"Cancer Immunol Res."},{"key":"1238_CR56","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13046-016-0320-4","volume":"35","author":"Y Chi","year":"2016","unstructured":"Chi Y, Zhou D. MicroRNAs in colorectal carcinoma-from pathogenesis to therapy. J Exp Clin Cancer Res. 2016;35:43.","journal-title":"J Exp Clin Cancer Res."},{"key":"1238_CR57","first-page":"4297","volume-title":"Down-regulation of tissue microRNA-126 was associated with poor prognosis in patients with cutaneous melanoma","author":"N Lin","year":"2015","unstructured":"Lin N, Zhou Y, Lian X, Tu Y. Down-regulation of tissue microRNA-126 was associated with poor prognosis in patients with cutaneous melanoma, vol. 8; 2015. p. 4297\u2013301."},{"key":"1238_CR58","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.gene.2017.06.055","volume":"627","author":"W Zhang","year":"2017","unstructured":"Zhang W, Zhou J, Zhu X, Yuan H. MiR-126 reverses drug resistance to TRAIL through inhibiting the expression of c-FLIP in cervical cancer. Gene. 2017;627:420\u20137.","journal-title":"Gene."},{"key":"1238_CR59","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.bbrc.2016.09.040","volume":"479","author":"P Wang","year":"2016","unstructured":"Wang P, Li Z, Liu H, Zhou D, Fu A, Zhang E. MicroRNA-126 increases chemosensitivity in drug-resistant gastric cancer cells by targeting EZH2. Biochem Biophys Res Commun. 2016;479:91\u20136.","journal-title":"Biochem Biophys Res Commun."},{"key":"1238_CR60","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.canlet.2017.02.025","volume":"394","author":"W Liu","year":"2017","unstructured":"Liu W, Chen H, Wong N, Haynes W, Baker CM, Wang X. Pseudohypoxia induced by miR-126 deactivation promotes migration and therapeutic resistance in renal cell carcinoma. Cancer Lett. 2017;394:65\u201375.","journal-title":"Cancer Lett."},{"key":"1238_CR61","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3389\/fgene.2018.00174","volume":"9","author":"F Baldassari","year":"2018","unstructured":"Baldassari F, Zerbinati C, Galasso M, Corr\u00e0 F, Minotti L, Agnoletto C, et al. Screen for MicroRNA and Drug Interactions in Breast Cancer Cell Lines Points to miR-126 as a Modulator of CDK4\/6 and PIK3CA Inhibitors. Front Genet. 2018;9:174.","journal-title":"Front Genet."},{"key":"1238_CR62","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s10637-016-0407-y","volume":"35","author":"MS Beg","year":"2017","unstructured":"Beg MS, Brenner AJ, Sachdev J, Borad M, Kang Y-K, Stoudemire J, et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs. 2017;35:180\u20138.","journal-title":"Invest New Drugs."},{"key":"1238_CR63","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","volume":"18","author":"N van Zandwijk","year":"2017","unstructured":"van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, Clarke S, et al. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 2017;18:1386\u201396.","journal-title":"Lancet Oncol."},{"key":"1238_CR64","doi-asserted-by":"publisher","first-page":"219","DOI":"10.15252\/emmm.201505774","volume":"9","author":"V Comunanza","year":"2017","unstructured":"Comunanza V, Cor\u00e0 D, Orso F, Consonni FM, Middonti E, Di Nicolantonio F, et al. VEGF blockade enhances the antitumor effect of BRAFV600E inhibition. EMBO Mol Med. 2017;9:219\u201337.","journal-title":"EMBO Mol Med."},{"key":"1238_CR65","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/bjc.2017.238","volume":"117","author":"R Bhattacharya","year":"2017","unstructured":"Bhattacharya R, Fan F, Wang R, Ye X, Xia L, Boulbes D, et al. Intracrine VEGF signalling mediates colorectal cancer cell migration and invasion. Br J Cancer. 2017;117:848\u201355.","journal-title":"Br J Cancer."},{"key":"1238_CR66","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1158\/0008-5472.CAN-15-1605","volume":"76","author":"R Bhattacharya","year":"2016","unstructured":"Bhattacharya R, Ye X-C, Wang R, Ling X, McManus M, Fan F, et al. Intracrine VEGF Signaling Mediates the Activity of Prosurvival Pathways in Human Colorectal Cancer Cells. Cancer Res. 2016;76:3014\u201324.","journal-title":"Cancer Res."},{"key":"1238_CR67","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1593\/neo.11948","volume":"14","author":"U Adamcic","year":"2012","unstructured":"Adamcic U, Skowronski K, Peters C, Morrison J, Coomber BL. The effect of bevacizumab on human malignant melanoma cells with functional VEGF\/VEGFR2 autocrine and intracrine signaling loops. Neoplasia. 2012;14:612\u201323.","journal-title":"Neoplasia."},{"key":"1238_CR68","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1371\/journal.pmed.0040186","volume":"4","author":"T-H Lee","year":"2007","unstructured":"Lee T-H, Seng S, Sekine M, Hinton C, Fu Y, Avraham HK, et al. Vascular Endothelial Growth Factor Mediates Intracrine Survival in Human Breast Carcinoma Cells through Internally Expressed VEGFR1\/FLT1. Kerbel RS, editor. PLoS Med. 2007;4:e186.","journal-title":"PLoS Med."},{"key":"1238_CR69","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","volume":"14","author":"G Siravegna","year":"2017","unstructured":"Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14:531\u201348.","journal-title":"Nat Rev Clin Oncol."},{"key":"1238_CR70","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13046-017-0598-x","volume":"36","author":"N Silvestris","year":"2017","unstructured":"Silvestris N, Ciliberto G, De Paoli P, Apolone G, Lavitrano ML, Pierotti MA, et al. Liquid dynamic medicine and N-of-1 clinical trials: a change of perspective in oncology research. J Exp Clin Cancer Res. 2017;36:128.","journal-title":"J Exp Clin Cancer Res"},{"key":"1238_CR71","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.4049\/jimmunol.1302616","volume":"192","author":"JS Wilmott","year":"2014","unstructured":"Wilmott JS, Haydu LE, Menzies AM, Lum T, Hyman J, Thompson JF, et al. Dynamics of Chemokine, Cytokine, and Growth Factor Serum Levels in BRAF-Mutant Melanoma Patients during BRAF Inhibitor Treatment. J Immunol. 2014;192:2505\u201313.","journal-title":"J Immunol."},{"key":"1238_CR72","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2217\/fon.15.290","volume":"12","author":"PA English","year":"2016","unstructured":"English PA, Williams JA, Martini J-F, Motzer RJ, Valota O, Buller RE. A case for the use of receiver operating characteristic analysis of potential clinical efficacy biomarkers in advanced renal cell carcinoma. Future Oncol. 2016;12:175\u201382.","journal-title":"Future Oncol."},{"key":"1238_CR73","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1172\/JCI66236","volume":"123","author":"DA Knight","year":"2013","unstructured":"Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, et al. Host immunity contributes to the antimelanoma activity of BRAF inhibitors. J Clin Invest. 2013;123:1371\u201381.","journal-title":"J Clin Invest."}],"container-title":["Journal of Experimental & Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-019-1238-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13046-019-1238-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-019-1238-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T23:11:09Z","timestamp":1592608269000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-019-1238-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,21]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1238"],"URL":"https:\/\/doi.org\/10.1186\/s13046-019-1238-4","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,21]]},"assertion":[{"value":"27 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with Good Clinical Practice Guidelines and the Declaration of Helsinki. The study was approved by the IDI-IRCCS Ethics Committee (ID #407\/1, 2013 and #407\/2, 2016) and a written informed consent was obtained from all patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"272"}}